
Medicines Patent Pool (MPP)

Scientific and Medical Affairs Manager in Mumbai | Medicines Patent Pool

Mumbai, Maharashtra · full-time · senior level · Competitive

Application Assist →

View on aikyamjobs.org



Skills this role needs

Clinical evidence review	Pharmaceutical pipeline intelligence	Scientific writing	Horizon scanning	Disease landscape analysis

Job description

Medicines Patent Pool

The Medicines Patent Pool is a public health organisation backed by the United Nations. It helps people in low- and middle-income countries (LMICs) get affordable, good-quality medicines and health tools. It does this by agreeing licences with drug makers and helping share the know-how needed to make medicines locally. It started with HIV (human immunodeficiency virus), hepatitis C and tuberculosis, and now also works on essential medicines, COVID-19 treatments, vaccines and preparing for future pandemics. This role sits within the Medicines Patent Pool's Scientific and Medical Affairs team, which studies the science and clinical evidence behind medicines to find where the organisation can do the most good for public health.

Role

As Scientific and Medical Affairs Manager, you will study existing and new medicines, including biologics and long-acting treatments, and judge how much they could help people in LMICs. You will review clinical evidence, track disease trends and follow what drug companies and research labs are developing. You will turn complex science into clear, timely advice that shapes which medicines the organisation works to license and make more widely available. The work mixes careful science with a strong focus on public health and fair access.

Responsibilities

- Assess candidate medicines, including biologics for infectious diseases, by reviewing study design, results, safety, dosing, how the medicine is given and who it is meant for.
- Compare each product with current and expected standard treatments, and point out its strengths, limits and evidence gaps for use in LMICs, including against national and international guidelines and essential medicines lists.
- Write and keep up to date short product profiles, and revise assessments when important new evidence comes out.
- Track disease burden, treatment gaps and unmet needs for HIV, viral hepatitis, RSV (respiratory syncytial virus), tuberculosis, malaria and other public health priorities, including changes in World Health Organization (WHO) guidelines.
- Monitor drug company, biotechnology and academic pipelines, clinical trials, regulatory news, scientific papers and conferences to spot promising medicines early.
- Support business development colleagues with scientific checks on individual medicines and company pipelines, and flag factors that affect manufacturing, approval and uptake.
- Coordinate with teams working on intellectual property, regulation, policy, market access and technology transfer, sharing scientific findings through clear memos and briefings.
- Prepare scientific inputs for the Scientific Advisory Panel, quarterly review meetings, donor reports, partners and communication materials, and attend events to gather insights for the team.

Requirements

- A master's, PhD or other advanced degree in biology, medicine, pharmacology or a related science.
- At least 5 years of experience in scientific assessment, clinical research, scientific intelligence, access programmes or a related area, including assessing clinical and scientific evidence for medicines.
- Strong analytical, scientific writing and summarising skills.
- Professional fluency in English and good digital skills.
- Experience with HIV, tuberculosis, viral hepatitis, respiratory infections, malaria or emerging infectious diseases is a plus.
- Experience working with LMIC health systems, global health partners and international, multidisciplinary teams is a plus, along with a sound understanding of drug development and regulatory processes.

- Based in or willing to relocate to Mumbai, with occasional international travel.

Benefits

- 30 days of paid annual leave plus local public holidays.
- Flexible working, including remote work options and part-time setups.
- Money and time set aside for your professional development and learning.
- A small, multicultural and inclusive team guided by the values of respect, courage, generosity and commitment.
- Meaningful work that helps bring life-saving medicines to the people who need them most.

Apply

Check your fit for the role and receive the apply link in your mailbox


Follow our WhatsApp Channel to get notified about the latest jobs.

About the organisation

Medicines Patent Pool (MPP)

Public Health / International Non-Profit

medicinespatentpool.org ↗
More on aikyamjobs.org



About Medicines Patent Pool (MPP)

Medicines Patent Pool (MPP) is a United Nations backed public health organisation that works to get affordable, quality assured versions of patented medicines to people in low and middle income countries. It does this by negotiating voluntary licenses with pharmaceutical companies that hold drug patents, then passing those licenses on to generic manufacturers who can produce and sell the medicines at a fraction of the original price.

India sits at the centre of how this model actually works. Most of the generic medicines that MPP licenses, for HIV, hepatitis C, tuberculosis, cancer and COVID-19, are manufactured by Indian pharmaceutical companies and exported from India to dozens of other countries. Firms such as Cipla, Aurobindo, Viatris, Mylan, Micro Labs, Emcure, Hetero, Eugia and Dr Reddy's Laboratories have all signed sublicence agreements with MPP over the years, making India the organisation's single largest manufacturing base. MPP has also engaged directly with India's own health priorities, including a 2023 statement by its Executive Director at the G20 Health Working Group meeting in Kerala, and ongoing coverage of India's hepatitis C elimination efforts through local partners such as the Apno ki Awaaz initiative.

> *Headquarters: Geneva, Switzerland*

Major Areas of Work

- HIV and hepatitis C treatment access: Licensing antiretrovirals and direct acting antivirals for generic production, with Indian manufacturers supplying much of the global generic HIV and hepatitis C medicine used in lower income countries.
- Tuberculosis treatment: Licensing investigational and existing TB medicines for wider, more affordable access.
- Cancer and non-communicable diseases: Extending the licensing model beyond infectious disease, including MPP's first cancer medicine licence (nilotinib), sublicensed to Indian firms Eugia, Hetero and Dr Reddy's Laboratories.
- Pandemic preparedness and technology transfer: Negotiating licenses for COVID-19 treatments and running an mRNA technology transfer programme, including agreements that brought Indian manufacturers into producing generic COVID-19 antivirals.
- Patent transparency and data tools: Running MedsPaL, a public database of patents and licences on essential medicines, now marking its tenth year.

Major Initiatives & Programmes

- Licensing for Public Health: MPP's core model of negotiating non-exclusive, voluntary licenses with originator companies and passing them to generic manufacturers, with Indian companies forming the largest group of sublicensees across nearly every disease area MPP covers.
- Long Acting Therapeutics and AccessPaL: Supporting newer, longer acting treatment options, including a 2023 sublicence agreement with Aurobindo, Cipla and Viatris to produce a generic version of a long acting HIV prevention medicine.
- COVID-19 antiviral access: Sublicensing generic versions of oral COVID-19 treatments to manufacturers worldwide, with reports naming 19 firms in India among those approved to produce the Pfizer antiviral for export.
- mRNA Technology Transfer Programme: Building regional capacity for mRNA vaccine and treatment manufacturing in low and middle income countries.
- Addressing Children's Needs: Prioritising child-friendly formulations of licensed medicines.

Impact

Nearly 2 billion people worldwide lack access to high quality essential medicines, and MPP's licensing model exists to close that gap, most visibly through India's generics industry. An annual course of HIV treatment that costs around USD 10,000 in Europe is available for under USD 70 in parts of Africa, a difference made possible largely because Indian manufacturers can produce the generic version under license. With around 40 million people living with HIV, 1.3 million annual deaths from hepatitis related causes, and 1.25 million annual TB deaths worldwide, the scale of what Indian generic production enables is significant. MPP has also documented this impact directly in India, producing a series of impact videos in 2020 featuring patients, doctors and government officials describing how access to quality assured HIV and hepatitis C generics changed outcomes on the ground.

Leadership

- Executive Director – Charles Gore
- Chair, Governance Board – Marie-Paule Kieny

Medicines Patent Pool is an excellent fit for professionals passionate about public health, pharmaceutical policy, patent law and global health equity, particularly anyone interested in how India's generic drug industry shapes access to medicine for millions of people worldwide.

Interested? Application Assist → · Full listing: https://aikyamjobs.org/jobs/scientific-and-medical-affairs-manager-in-mumbai-medicines-patent-pool